October 30, 2016 - Curasight

Skip to main content Skip to navigation Skip to search

About Us
Technology
Pipeline
- Programmes
News
Investor
Contact

Home
News
News
2016
October 30, 2016

Press releases
News
Curasight in the Media
Conferences
Subscribe

October 30, 2016

October 30, 2016

Our phase I study just published online in Journal of Nuclear Medicine

E-mail LinkedIn

Curasight is a pioneer in the field of exploiting a novel PET imaging target – the urokinase-type plasminogen activator receptor (uPAR) – for improved prostate cancer diagnose.

Subscribe

Subscribe to get the latest news first.

Choose type

Financial reports Press releases

E-mail

Something went wrong - please make sure you entered the correct email.

Thank you. You will get an e-mail message to activate your subscription.

News
Contact
Terms of use

Copyright 2021 © Curasight

This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. Read more about cookies here